Drug Type Fluorophore-conjugated therapeutics |
Synonyms ASP 5354, ASP-5354, ASP5354 |
Target- |
Mechanism Diagnostic dye |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC135H197ClN4O73 |
InChIKeyAPOUWPLRCFRTJM-BLXIHOOASA-N |
CAS Registry2243793-22-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Kidney Diseases | Phase 3 | US | 19 Mar 2024 | |
Ureteral Diseases | Phase 3 | US | 02 Aug 2023 | |
Breast Cancer | Phase 2 | US | 10 Aug 2022 | |
Melanoma | Phase 2 | US | 10 Aug 2022 | |
Renal Insufficiency | Phase 1 | US | 25 Aug 2022 | |
Renal Insufficiency | Phase 1 | JP | 25 Aug 2022 |
Phase 2 | 1 | ueupdaixnq(bhojgzepwc) = arwasappsz vsenspkeaa (avzxmqpeyq, wogopnguwv - nzleiqdkeu) View more | - | 01 May 2024 | |||
Phase 2 | - | 13 | (Pudexacianinium Chloride - Dose Level A) | ntdcrgoqds(jlwpdvqwhf) = lyhdpatsfu vfkcnthdps (ckxzvbyhza, vvdawzmyjc - utdcnvwhwu) View more | - | 13 Feb 2023 | |
(Pudexacianinium Chloride - Dose Level B) | ntdcrgoqds(jlwpdvqwhf) = rfjszxwanu vfkcnthdps (ckxzvbyhza, ihmvbaasep - yltcijnxut) View more | ||||||
NCT04238481 (NEWS) Manual | Phase 2 | - | rhzshggqyr(jcrjtezvlk) = mghpugacqr ppgqkacoxn (kaayufmujv ) View more | Positive | 31 Mar 2022 |